Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect - StockStory

📅 Moderna is scheduled to report quarterly earnings results this Friday morning.

💰 Last quarter, the company beat revenue expectations with $678 million reported despite a 29.8% year-on-year decrease.

🎯 This quarter, analysts expect revenue to grow significantly by 131% year on year, reversing last year's decline.

⚠️ Analyst sentiment is increasingly bearish with downward revenue revisions over the past 30 days.

🤝 Peers like Biogen and AbbVie reported their Q1 results recently, providing some market context for comparisons.

📉 Investors have shown mixed sentiment in the biotech sector, with Moderna down 10.4% this month while peers gained 6.4%.

💵 The average analyst price target is $41.42, which is below the current stock price of $45.54.

📜 The company has a history of rarely missing Wall Street's revenue estimates historically.

Bullish Signals
  • Moderna beat analysts' revenue expectations last quarter, reporting revenues of $678 million with a beat of analysts' EPS and revenue estimates.
  • Market expectations for this quarter show Moderna's revenue growing 131% year on year, representing a significant reversal from the 35.3% decrease recorded in the same quarter last year.
  • Moderna rarely misses Wall Street's revenue estimates, indicating consistent operational strength despite broader market headwinds.
Risk Factors
  • Moderna's revenue dropped 29.8% year on year, despite beating estimates last quarter.
  • Analysts have grown increasingly bearish with majority downward revisions to revenue estimates over the last 30 days.
  • The stock is down 10.4% over the last month compared to the broader biotechnology segment which rose 6.4%.
  • Current share price of $45.54 trades above the average analyst price target of $41.42, suggesting potential downside if earnings are missed.
  • Last quarter's revenue growth was 35.3% decline, with market now expecting a strong 131% reversal which may not materialize given peer performance like Biogen beating expectations by only 11.2% or AbbVie missing estimates by 5.2%.
Full Analysis
Biotechnology company Moderna (NASDAQ: MRNA) is preparing to report earnings this Friday morning, with market expectations for a significant shift from last year's performance. Analysts anticipate Moderna’s revenue will grow 131% year on year, marking a reversal from the 35.3% decrease recorded in the same quarter last year. However, recent analyst sentiment has turned increasingly bearish, as revenue estimates have seen majority downward revisions over the past 30 days. Notably, Moderna previously beat analysts’ revenue expectations by reporting $678 million, which represented a 29.8% decline year on year, yet it still exceeded EPS and revenue estimates at that time. Comparative performance among peers provides some context as Biogen delivered a 1.9% year-on-year revenue growth and AbbVie reported revenues up 4.8%, though both had varying impacts relative to their respective estimates with Biogen beating expectations by 11.2% and AbbVie falling short by 5.2%. The broader biotechnology sector has shown positive momentum, with share prices rising an average of 6.4% over the last month, while Moderna has declined 10.4% during the same period. Heading into earnings, the company currently trades at a price of $45.54 against an average analyst price target of $41.42, reflecting current market skepticism despite its historical track record of rarely missing Wall Street revenue estimates. Investors are watching closely as this upcoming report could define the trajectory for Moderna’s stock and position relative to competitors like Biogen and AbbVie who have recently released their Q1 results. The expectation for a 131% revenue increase is substantial, yet the recent downward revisions in analyst estimates suggest caution may prevail in how the market interprets these figures upon release. With biotech investors showing resilience in the sector generally, Moderna’s performance could either solidify its standing as a resilient player or highlight ongoing challenges that have not yet fully impacted its bottom line.